Successful use of nitazoxanide in the treatment of recurrent Clostridium difficile infection

BMJ Case Reports

Volumn , Issue , 2011, Pages

  Rafiullah, Fnu ^a   Kanwal, Sunil ^b   Majeed, Usman M ^c   Korsten, Mark A ^d   Cheema, Faisal H ^a   Luthra, Munish ^a   Sohail, Muhammad Rizwan ^e  

^a James J Peters VA MC ^*  (United States)

^b College of Physicians and Surgeons of Columbia University ^*  (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e Mayo Clinic MN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; CLOSTRIDIUM TOXIN; CONTRAST MEDIUM; HYDROCORTISONE; LEVOFLOXACIN; LOPERAMIDE; METRONIDAZOLE; NITAZOXANIDE; SERUM ALBUMIN; VANCOMYCIN;

ABDOMINAL CRAMP; ABDOMINAL DISTENSION; ABDOMINAL TENDERNESS; AGED; ANOREXIA; ARTICLE; BLOODY DIARRHEA; CASE REPORT; CAUCASIAN; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY ACQUIRED PNEUMONIA; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIARRHEA; DIFFERENTIAL DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE; FOLLOW UP; HUMAN; INTESTINE OBSTRUCTION; LEUKOCYTE; LEUKOCYTE COUNT; MALE; NAUSEA; NEUTROPHIL COUNT; PRIORITY JOURNAL; PROCTITIS; RADIATION PROCTITIS; RECURRENT INFECTION; REHABILITATION CARE; RELAPSE;

EID: 84855458409     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr.04.2011.4123     Document Type: Article

References (28)

1. Kyne L, Kelly CP. Recurrent Clostridium difficile diarrhoea. Gut 2001;49:152-3. (Pubitemid 32601893)
2. Kelly CP. A 76-year-old man with recurrent Clostridium difficile-associated diarrhea: review of C. difficile infection. JAMA 2009;301:954-62.
3. Zilberberg MD, Shorr AF, Kollef MH. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005. Emerg Infect Dis 2008;14:929-31. (Pubitemid 351838602)
4. Ricciardi R, Rothenberger DA, Madoff RD, et al. Increasing prevalence and severity of Clostridium difficile colitis in hospitalized patients in the United States. Arch Surg 2007;142:624-31; discussion 631.
5. Clabots CR, Johnson S, Olson MM, et al. Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection. J Infect Dis 1992;166:561-7.
6. Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis 2005;5:549-57. (Pubitemid 41196754)
7. Weir E, Flegel K. Protecting against Clostridium difficile illness. CMAJ 2005;172:1178. (Pubitemid 40592670)
8. Poutanen SM, Simor AE. Clostridium difficile-associated diarrhea in adults.CMAJ 2004;171:51-8. (Pubitemid 38925121)
9. Kyne L, Warny M, Qamar A, et al. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000;342:390-7. (Pubitemid 30084537)
10. Centers for Disease Control and Prevention (CDC). Severe Clostridium difficile-associated disease in populations previously at low risk - four states, 2005. MMWR Morb Mortal Wkly Rep 2005;54:1201-5.
11. Bartlett JG, Gerding DN. Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis 2008;46 Suppl 1:S12-8. (Pubitemid 351323661)
12. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 1994;330:257-62. (Pubitemid 24034138)
13. Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 2002;346:334-9.
14. Dallal RM, Harbrecht BG, Boujoukas AJ, et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 2002;235:363-72. (Pubitemid 34183887)
15. Stamper PD, Alcabasa R, Aird D, et al. Comparison of a commercial real-time PCR assay for tcdB detection to a cell culture cytotoxicity assay and toxigenic culture for direct detection of toxin-producing Clostridium difficile in clinical samples. J Clin Microbiol 2009;47:373-8.
16. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010;31:431-55.
17. Zar FA, Bakkanagari SR, Moorthi KM, et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45:302-7. (Pubitemid 47101025)
18. Kelly CP, LaMont JT. Clostridium difficile-more difficult than ever. N Engl J Med 2008;359:1932-40.
19. Issack MI, Elliott TS. Clostridium difficile carriage after infection. Lancet 1990;335:610-1. (Pubitemid 20089293)
20. Maroo S, Lamont JT. Recurrent clostridium difficile. Gastroenterology 2006;130:1311-6.
21. Fekety R, McFarland LV, Surawicz CM, et al. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis 1997;24:324-33. (Pubitemid 27096783)
22. Walters BA, Roberts R, Stafford R, et al. Relapse of antibiotic associated colitis: endogenous persistence of Clostridium difficile during vancomycin therapy. Gut 1983;24:206-12. (Pubitemid 13147734)
23. Wilcox MH, Fawley WN, Settle CD, et al. Recurrence of symptoms in Clostridium difficile infection-relapse or reinfection? J Hosp Infect 1998;38:93-100. (Pubitemid 28143351)
24. Sanchez J, Fnu R, Sunil K, et al. Metronidazole susceptibility in Clostridium difficile isolates recovered from cases of C. difficile-associated disease treatment failures and successes. Anaerobe 1999;5:201-4. (Pubitemid 30088856)
25. Gerding DN, Muto CA, Owens RC Jr. Treatment of Clostridium difficile infection. Clin Infect Dis 2008;46 Suppl 1:S32-42. (Pubitemid 351323663)
26. Musher DM, Logan N, Bressler AM, et al. Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. Clin Infect Dis 2009;48:e41-6.
27. Musher DM, Logan N, Hamill RJ, et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis 2006;43:421-7. (Pubitemid 44157148)
28. Peláez T, Alcalá L, Alonso R, et al. In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole. Antimicrob AgentsChemother 2005;49:1157-9. (Pubitemid 40327739)